Immune checkpoint inhibitors (ICIs) that block programmed cell death 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1), either as single agents or in combination, have led to revolutionary treatments for NSCLC.3, 4, 5, 6, 7. The gene discussed is CD274; the disease is non-small cell lung carcinoma.